Discover open access scientific publications

Efficacy and Safety of Adding an Agent to Bevacizumab/Taxane Regimens for the First-Line Treatment of Her2-Negative Patients With Locally Recurrent or Metastatic Breast Cancer: Results From Seven Randomized Controlled Trials